EZH2 and cancer: Beyond EZH2, overexpression of another Polycomb protein in PRC1, chromobox homolog protein 2 (CBX2), is also associated with poor survival by maintaining CSCs, which might be an emerging approach targeting Polycomb proteins that could be used in cancer therapy [191].